Literature DB >> 31171383

Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Reese Hitchings1, Libusha Kelly2.   

Abstract

Our bodies each possess a unique and dynamic collection of microbes and viruses, collectively the 'microbiome', with distinct metabolic capacities from our human cells. Unforeseen modification of drugs by the microbiome can drastically alter their clinical effectiveness, with the most dramatic cases leading to fatal drug interactions. Pharmaceuticals can be activated, deactivated, toxified, or release metabolites that alter the 'canonical' pharmacokinetics of the drug. Thus, predicting and characterizing microbe-drug interactions is necessary to develop and implement personalized drug administration protocols and, more broadly, to improve drug safety and efficacy. In this review, we focus on microbiome-driven alterations to drug pharmacokinetics and provide a research framework for pharmacologists interested in characterizing microbiome interactions with any drug of interest.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  microbiome; pharmacodynamics; pharmacology; xenobiotics

Mesh:

Substances:

Year:  2019        PMID: 31171383      PMCID: PMC6758919          DOI: 10.1016/j.tips.2019.04.014

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  86 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.

Authors:  Tim O Lankisch; Christoph Schulz; Thomas Zwingers; Thomas J Erichsen; Michael P Manns; Volker Heinemann; Christian P Strassburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

3.  Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.

Authors:  Yoshie Masaoka; Yusuke Tanaka; Makoto Kataoka; Shinji Sakuma; Shinji Yamashita
Journal:  Eur J Pharm Sci       Date:  2006-06-27       Impact factor: 4.384

4.  Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

Authors:  J Kirchheiner; H Schmidt; M Tzvetkov; J-T H A Keulen; J Lötsch; I Roots; J Brockmöller
Journal:  Pharmacogenomics J       Date:  2006-07-04       Impact factor: 3.550

5.  Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.

Authors:  M Pierantozzi; A Pietroiusti; L Brusa; S Galati; A Stefani; G Lunardi; E Fedele; G Sancesario; G Bernardi; A Bergamaschi; A Magrini; P Stanzione; A Galante
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

Review 6.  Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.

Authors:  Elizabeth A Sconce; Farhad Kamali
Journal:  Eur J Haematol       Date:  2006-10-17       Impact factor: 2.997

7.  ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?

Authors:  Tingjun Hou; Junmei Wang; Wei Zhang; Xiaojie Xu
Journal:  J Chem Inf Model       Date:  2007 Mar-Apr       Impact factor: 4.956

8.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

9.  Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration.

Authors:  Albert-Jan L H J Aarnoudse; Jeanne P Dieleman; Loes E Visser; Pascal P Arp; Ilse P van der Heiden; Ron H N van Schaik; Mariam Molokhia; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Journal:  Pharmacogenet Genomics       Date:  2008-04       Impact factor: 2.089

10.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

View more
  10 in total

1.  UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro.

Authors:  Ji Li; Zhangyao Xu; Jifeng Gu
Journal:  Molecules       Date:  2022-06-26       Impact factor: 4.927

Review 2.  Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities.

Authors:  Saad Khan; Ruth Hauptman; Libusha Kelly
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-10-13       Impact factor: 16.459

Review 3.  Drugs and Bugs: The Gut-Brain Axis and Substance Use Disorders.

Authors:  Sierra Simpson; Rio Mclellan; Emma Wellmeyer; Frederic Matalon; Olivier George
Journal:  J Neuroimmune Pharmacol       Date:  2021-10-25       Impact factor: 7.285

4.  Harnessing machine learning for development of microbiome therapeutics.

Authors:  Laura E McCoubrey; Moe Elbadawi; Mine Orlu; Simon Gaisford; Abdul W Basit
Journal:  Gut Microbes       Date:  2021 Jan-Dec

5.  Involvement of Abnormal Gut Microbiota Composition and Function in Doxorubicin-Induced Cardiotoxicity.

Authors:  Jie Huang; Shanshan Wei; Chuanhao Jiang; Zijun Xiao; Jian Liu; Weijun Peng; Bikui Zhang; Wenqun Li
Journal:  Front Cell Infect Microbiol       Date:  2022-02-25       Impact factor: 5.293

Review 6.  Human Gut Microbiota and Drug Metabolism.

Authors:  Archana Pant; Tushar K Maiti; Dinesh Mahajan; Bhabatosh Das
Journal:  Microb Ecol       Date:  2022-07-23       Impact factor: 4.192

Review 7.  Probiotics: Protecting Our Health from the Gut.

Authors:  Gael Urait Varela-Trinidad; Carolina Domínguez-Díaz; Karla Solórzano-Castanedo; Liliana Íñiguez-Gutiérrez; Teresita de Jesús Hernández-Flores; Mary Fafutis-Morris
Journal:  Microorganisms       Date:  2022-07-14

8.  Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines.

Authors:  Chuan Li; Wei-Wei Jia; Jun-Ling Yang; Chen Cheng; Olajide E Olaleye
Journal:  Acta Pharmacol Sin       Date:  2022-09-16       Impact factor: 7.169

9.  Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota.

Authors:  Laura E McCoubrey; Stavriani Thomaidou; Moe Elbadawi; Simon Gaisford; Mine Orlu; Abdul W Basit
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

10.  Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis.

Authors:  Shuting Wen; Long He; Zhuotai Zhong; Runyuan Zhao; Senhui Weng; Hong Mi; Fengbin Liu
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.